Application of butyrolactone compounds to preparation of antituberculosis drugs
Butyrolactone compounds isolated from marine microorganisms have significant inhibitory activity against Mycobacterium tuberculosis tyrosine phosphatase, which solves the problem of difficulty in effectively targeting this enzyme with existing anti-tuberculosis drugs and provides new opportunities for the development of anti-tuberculosis drugs. direction.
Patent Information
- Application Number
- CN201610217872.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2016-04-11
- Publication Date
- 2017-10-24
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Tuberculosis is prone to drug resistance, and it is difficult to effectively target Mycobacterium tuberculosis tyrosine phosphatase in the development of existing anti-tuberculosis drugs, resulting in poor therapeutic effects and a lack of effective new inhibitors.
Butyrolactone compounds (Formula I-Formula VI) isolated from marine microorganisms, especially have significant inhibitory activity against Mycobacterium tuberculosis tyrosine phosphatase (mPTPB), and serve as potential anti-tuberculosis drug targets.
These compounds have significant inhibitory activity against Mycobacterium tuberculosis tyrosine phosphatase, provide a new direction for the development of anti-tuberculosis drugs, and have broad application prospects.
